Abstract
Rapamycin, an mTOR inhibitor and immunosuppressive agent in clinic, has protective effects on traumatic brain injury and neurodegenerative diseases. But, its effects on transient focal ischemia/reperfusion disease are not very clear. In this study, we examined the effects of rapamycin preconditioning on mice treated with middle cerebral artery occlusion/reperfusion operation (MCAO/R). We found that the rapamycin preconditioning by intrahippocampal injection 20 hr before MCAO/R significantly improved the survival rate and longevity of mice. It also decreased the neurological deficit score, infracted areas and brain edema. In addition, rapamycin preconditioning decreased the production of NF-κB, TNF-α, and Bax, but not Bcl-2, an antiapoptotic protein in the ischemic area. From these results, we may conclude that rapamycin preconditioning attenuate transient focal cerebral ischemia/reperfusion injury and inhibits apoptosis induced by MCAO/R in mice.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Apoptosis / drug effects
-
Brain Edema / etiology
-
Brain Edema / prevention & control
-
Brain Infarction / etiology
-
Brain Infarction / prevention & control
-
Disease Models, Animal
-
Female
-
Gene Expression Regulation / drug effects
-
Hippocampus / drug effects
-
Hippocampus / physiology
-
Infarction, Middle Cerebral Artery / blood
-
Infarction, Middle Cerebral Artery / mortality
-
Infarction, Middle Cerebral Artery / prevention & control*
-
Male
-
Mice
-
Mice, Inbred BALB C
-
NF-kappa B / blood
-
Nervous System Diseases / etiology
-
Nervous System Diseases / prevention & control
-
Neurologic Examination
-
Reperfusion Injury / complications
-
Reperfusion Injury / mortality
-
Reperfusion Injury / prevention & control*
-
Sirolimus / therapeutic use*
-
Survival Rate
-
Tumor Necrosis Factor-alpha / blood
-
bcl-2-Associated X Protein / blood
Substances
-
NF-kappa B
-
Tumor Necrosis Factor-alpha
-
bcl-2-Associated X Protein
-
Sirolimus